Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- COVID-19
- Seasonal Influenza
May 10, 2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan
- Statement
- COVID-19
May 7, 2021
Novavax Statement in Opposition to the WTO TRIPS Waiver
- Statement
- COVID-19
May 7, 2021
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
- COVID-19
May 6, 2021
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

May 5, 2021
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

May 3, 2021
Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021

Apr 23, 2021
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
- Matrix-M™ Adjuvant
Apr 23, 2021
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
- COVID-19
Apr 14, 2021
Novavax Announces Leadership Updates
- Corporate and Finance
Apr 13, 2021

Show per page